Speaking from the 2018 European Society for Blood and Marrow Transplantation (EBMT) Annual Meeting in Lisbon, Portugal, Daniel DeAngelo, MD, PhD, of the Dana-Farber Cancer Institute, Boston, MA, outlines the range of novel therapies on the horizon for treating relapsed/refractory acute lymphoblastic leukemia (ALL), including monoclonal antibody-drug conjugates and CAR T-cells.
Novel therapies for treating relapsed/refractory ALL
